AMB-05X for colorectal cancer with ctDNA after treatment
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called AMB-05X for people with colorectal cancer who have completed all intended treatments and show no signs of cancer on scans, but still have cancer DNA (ctDNA) in their blood. The goal is to see if AMB-05X can eliminate this remaining cancer DNA and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colon or rectal cancer (adenocarcinoma).
- You have finished all planned treatments (like surgery or chemotherapy) and are currently cancer-free on scans.
- You have a positive ctDNA (Signatera) blood test after completing your treatments, showing there may still be cancer cells.
- You are 18 years or older.
- You are in good enough health to walk and take care of yourself (ECOG score 0 or 1).
- You have adequate kidney, liver, and blood cell function as determined by routine lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests TAS-102, with or without celecoxib, to treat “minimal residual disease” (tiny traces of colon cancer) found in a blood test after standard chemotherapy. The goal is to reduce the chance that colon cancer returns after treatment.
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.